Cornercap Investment Counsel Inc. grew its holdings in Eli Lilly and Co (NYSE:LLY) by 27.3% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 44,386 shares of the company’s stock after acquiring an additional 9,515 shares during the quarter. Cornercap Investment Counsel Inc.’s holdings in Eli Lilly and were worth $3,748,000 as of its most recent SEC filing.
Several other institutional investors have also made changes to their positions in the company. Guggenheim Capital LLC boosted its position in shares of Eli Lilly and by 21.5% in the fourth quarter. Guggenheim Capital LLC now owns 701,899 shares of the company’s stock valued at $59,283,000 after acquiring an additional 124,217 shares during the period. QS Investors LLC boosted its position in shares of Eli Lilly and by 1.7% in the fourth quarter. QS Investors LLC now owns 100,215 shares of the company’s stock valued at $8,464,000 after acquiring an additional 1,685 shares during the period. Franklin Resources Inc. boosted its position in shares of Eli Lilly and by 2.7% in the fourth quarter. Franklin Resources Inc. now owns 28,519,524 shares of the company’s stock valued at $2,408,787,000 after acquiring an additional 754,681 shares during the period. Ironvine Capital Partners LLC bought a new stake in shares of Eli Lilly and in the fourth quarter valued at about $399,000. Finally, Caxton Associates LP bought a new stake in shares of Eli Lilly and in the fourth quarter valued at about $1,371,000. 76.79% of the stock is owned by institutional investors.
In other Eli Lilly and news, insider Donald A. Zakrowski sold 860 shares of the business’s stock in a transaction dated Thursday, March 1st. The stock was sold at an average price of $76.50, for a total transaction of $65,790.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Donald A. Zakrowski sold 876 shares of the business’s stock in a transaction dated Wednesday, February 21st. The stock was sold at an average price of $77.55, for a total value of $67,933.80. Following the transaction, the insider now directly owns 4,130 shares of the company’s stock, valued at approximately $320,281.50. The disclosure for this sale can be found here. In the last three months, insiders have sold 212,261 shares of company stock valued at $18,627,485. Insiders own 0.20% of the company’s stock.
Eli Lilly and (NYSE:LLY) last issued its earnings results on Wednesday, January 31st. The company reported $1.14 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.08 by $0.06. The firm had revenue of $6.16 billion during the quarter, compared to the consensus estimate of $5.93 billion. Eli Lilly and had a positive return on equity of 33.01% and a negative net margin of 0.89%. The business’s quarterly revenue was up 7.0% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.95 earnings per share. sell-side analysts forecast that Eli Lilly and Co will post 4.87 EPS for the current year.
A number of equities research analysts have recently issued reports on the stock. TheStreet cut shares of Eli Lilly and from a “b” rating to a “c” rating in a research report on Monday, March 5th. Jefferies Group set a $93.00 target price on shares of Eli Lilly and and gave the company a “buy” rating in a research report on Monday, February 26th. JPMorgan Chase & Co. set a $105.00 target price on shares of Eli Lilly and and gave the company a “buy” rating in a research report on Monday, February 26th. Credit Suisse Group reaffirmed a “hold” rating and set a $80.00 price objective on shares of Eli Lilly and in a research report on Friday, February 2nd. Finally, Bank of America cut their price objective on shares of Eli Lilly and from $88.00 to $86.00 and set a “neutral” rating for the company in a research report on Thursday, February 1st. Two equities research analysts have rated the stock with a sell rating, eight have issued a hold rating and ten have given a buy rating to the company. The stock currently has an average rating of “Hold” and an average target price of $93.47.
COPYRIGHT VIOLATION NOTICE: This article was originally posted by Sports Perspectives and is the sole property of of Sports Perspectives. If you are accessing this article on another site, it was illegally stolen and reposted in violation of United States & international trademark & copyright law. The legal version of this article can be viewed at https://sportsperspectives.com/2018/03/12/cornercap-investment-counsel-inc-acquires-9515-shares-of-eli-lilly-and-co-lly.html.
Eli Lilly and Company Profile
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Co (NYSE:LLY).
Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.